FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
Feed↓
/ What's going on?
Filter:
DraftKings Teams Up With Crypto.com for Expanded Prediction Markets
DraftKings (DKNG) partners with Crypto.com to expand prediction markets, adding player-specific sports contracts and new categories including politics and entertainment.
Pfizer’s Chantix Move Seen as Positive Signal for Achieve Life Sciences
Analysts say Pfizer listing Chantix on TrumpRx may support Achieve Life Sciences and boost confidence in cytisinicline’s approval prospects.
Hellman & Friedman Eyes Acquisition of Bill Holdings Amid Activist Pressure
Private equity firm Hellman & Friedman is in talks to buy Bill Holdings Inc., a business payments company valued at $4.2 billion, as activist investors push for change.
Trump Team Eyes Antitrust Probe Into Major US Homebuilders
The Trump administration is considering investigating large homebuilders over potential price coordination and supply restrictions as housing affordability worsens across America.
Hims vs. Novo Nordisk: Why the Pharma Giant Might Avoid a Legal Fight
Hims is selling a $49 copycat of Novo Nordisk's $149 weight-loss pill, but legal experts say Novo may avoid court battles due to risks of setting dangerous precedents.